Moxifloxacino frente a amoxicilina en el tratamiento de la neumonía adquirida en la comunidad en América Latina. Resultados de un ensayo clínico multicéntrico

Jardim, José R.; Rico, Gerardo; Roza, Cristian de la; Obispo, E.; Urueta, Juan; Wolff, Marcelo; Miravitlles, Marc

doi:10.1016/s0300-2896(03)75413-1

Archivos de Bronconeumología

2003

DOI: 10.1016/s0300-2896(03)75413-1

|View full text |Cite

Moxifloxacino frente a amoxicilina en el tratamiento de la neumonía adquirida en la comunidad en América Latina. Resultados de un ensayo clínico multicéntrico

José R. Jardim

Gerardo Rico

Cristian de la Roza

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2005

2013

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 9 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A search for the appropriate antimicrobial agent motivated an international clinical trial to evaluate the efficacy and safety of treatment with moxifloxacin in comparison with amoxicillin in patients suspected of pneumococcal CAP. 43 That study reflected experience in 5 Latin American countries, listing germs isolated, patterns of antibiotic sensitivity, and clinical and microbiological findings. The high prevalence of S pneumoniae with low susceptibility to penicillin was documented and should be taken into account in establishing empirical treatment guidelines for those countries.…”

mentioning

confidence: 80%

Pneumonia Awareness Year, 2004: Scientific Impact Through Publications in Archivos de Bronconeumología

Naranjo

Marco

2006

Archivos de Bronconeumología ((English Edition))

View full text Add to dashboard Cite

Pneumonia is a common and potentially serious infectious disease. Morbidity and mortality rates continue to be high in spite of major advances and steady progress in diagnosis and treatment. The economic impact of the disease is also great. It is therefore necessary to enlist the public, primary care and emergency physicians, and public policy administrators to join forces to treat and prevent pneumonia for the common good. The annual incidence of pneumonia in the population over the age of 14 years is 1.6 to 2.6 episodes/1000 inhabitants. The mortality rate is 14.1 per 100,000 inhabitants, and the associated costs are 115 million euros annually. The RESPIRA Foundation and the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) declared 2004 to be pneumonia awareness year with the aim of coordinating efforts to raise awareness, distribute information, and foster debate.

show abstract

mentioning

confidence: 80%

Pneumonia Awareness Year, 2004: Scientific Impact Through Publications in Archivos de Bronconeumología

Naranjo

Marco

2006

Archivos de Bronconeumología ((English Edition))

View full text Add to dashboard Cite

show abstract

Empirical Atypical Coverage for Inpatients With Community-Acquired Pneumonia

Shefet¹,

Robenshtok²,

Leibovici³

2005

Arch Intern Med

View full text Add to dashboard Cite

show abstract

Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors

Portier

Brambilla²,

Garré

et al. 2005

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

The objective of this study was to assess the efficacy and safety of moxifloxacin versus amoxicillin-clavulanate plus roxithromycin (comparator) in adult community-acquired pneumonia (CAP) patients with risk factors. In this comparative, randomized, multicenter, open-label study, patients hospitalized for CAP received a 10-day oral treatment with either moxifloxacin (400 mg o.d.) or amoxicillin-clavulanate (1,000/125 mg t.i.d.) plus roxithromycin (150 mg b.i.d.). Clinical and bacteriological outcomes were assessed during test of cure and follow-up visits (5-7 days and 21-28 days after the end of treatment, respectively). Of 349 randomized patients, 346 were included in the intent-to-treat analysis and 289 in the per-protocol analysis. Their baseline characteristics were comparable. The most frequent risk factors for mortality were age >65 years (50.0%), alcoholism (23.1%), and comorbidities (50.6%); chronic obstructive pulmonary disease (COPD) (25.4%) and diabetes mellitus (13.6%) were the most common associated comorbidities. A causative pathogen was documented in 66 of 346 (19.1%) of the patients (including 21 with positive blood cultures). Respective per-protocol clinical success rates at test-of-cure (primary efficacy endpoint) for moxifloxacin and comparator were 131 of 151 (86.8%) and 120 of 138 (87.0%), with a 95% confidence interval (CI) of -8.0-7.6 for the difference. Bacteriological success rates (eradication) were 23 of 30 (76.7%) and 23 of 31 (74.2%); rates for patients with positive blood cultures were 10 of 14 and 4 of 6. Persistent clinical success rates at follow-up were 118 of 120 (98.3%) and 102 of 106 (96.2%), with a 95%CI of -2.2-6.4 for the difference. The intent-to-treat analysis confirmed these results. Adverse events associated with moxifloxacin and the comparator drug were reported for 42 of 171 (24.6%) and 50 of 175 (28.6%) of the patients, respectively, and comprised predominantly digestive disorders, which occurred in 9.4% and 21.1%. On the basis of these results, once-daily oral moxifloxacin alone is as effective as amoxicillin-clavulanate plus roxithromycin for the treatment of CAP in patients with risk factors.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Moxifloxacino frente a amoxicilina en el tratamiento de la neumonía adquirida en la comunidad en América Latina. Resultados de un ensayo clínico multicéntrico

Cited by 9 publications

References 39 publications

Pneumonia Awareness Year, 2004: Scientific Impact Through Publications in Archivos de Bronconeumología

Pneumonia Awareness Year, 2004: Scientific Impact Through Publications in Archivos de Bronconeumología

Empirical Atypical Coverage for Inpatients With Community-Acquired Pneumonia

Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors

Contact Info

Product

Resources

About